The passage of HB 4327 is a significant and long-overdue win for transparency, accountability, and — most importantly — for Illinois patients.
For the first time, Illinois will have an independent, standardized accounting of how the 340B program actually operates in our state: where the money flows, how contract pharmacies and third-party administrators are compensated, and whether the program is delivering on its core mission of serving vulnerable patients.
We have said from the beginning — and we will say it again today — that transparency must come before policy change, not after. That principle is now embedded in Illinois law.
The reporting framework in HB 4327 didn’t emerge out of nowhere. Similar language was proposed during negotiations over HB 2371 more than a year ago and was stripped out. Representative Deuter introduced HB 4594 and Senator Adrianne Johnson introduced SB 3146 earlier this year. Multiple independent study proposals were put forward in the House. The fact that we are here now — with a transparency bill finally advancing — is a reflection of persistent advocacy by legislators and stakeholders who believed the public deserved to know what is happening inside this program.
What states like Minnesota have already found is instructive: PBMs and large contract pharmacy chains have been capturing a disproportionate share of 340B revenue at the expense of FQHCs and smaller safety-net providers — the very entities the program was designed to support. HB 4327 will shine that same light on Illinois, and the data will tell us whether the same abuses are happening here.
On HB 2371 — iBIO’s position has been consistent. Major policy changes to a multi-billion-dollar federal program should be grounded in data and accountability. We continue to believe the reporting framework should inform and shape any further reforms. We will be watching closely to ensure the reporting requirements in HB 4327 are implemented with rigor and independence, and that the results drive evidence-based policy going forward.
I want to thank Leader Lilly for her leadership in getting HB 4327 across the finish line. Illinois patients and taxpayers deserve to know how this program is working — and now, we will find out.
John Conrad is President & CEO of the Illinois Biotechnology Innovation Organization (iBIO), the state trade association representing the life sciences industry in Illinois.